Blood/vessel wall cell interactions depend, in part, on the expression of adhesion receptors on cell surfaces, such as expression of the vitronectin receptor (VnR) on the apical surface of endothelial cells (ECs) for platelet/EC adhesion. However, it is unclear how receptor expression is regulated from within cells. In previous studies, we found that ECs metabolize linoleic acid into the lipoxygenase monohydroxide, 13-hydroxyoctadecadienoic acid (1 3-HODE), and that the intracellular level of 13-HODE correlates inversely with VnR expression and platelet adhesion to the EC apical surface. In this study, we determined the physical associations of 13-HODE and VnR in unstimulated and stimulated ECs, ie, at times when ECs were and were not adhesive for specific ligands and platelets, using double antibody immunofluorescent staining techniques and binding assays. 13-HE INTACT endothelial cell (EC) lining of the vascu-T lar wall is not reactive to the circulating blood However, ECs acquire thrombogenic properties when they are stimulated by cytokines or thrombin, as shown both in vivo and in vitro. Thus, there is expression of plasminogen activator inhibit~r,~ expression of tissue f a~t o r ,~ and downregulation of thrombomod~lin,~ all of which can facilitate thrombogenesis. We have made a number of observations that suggest that changes in EC lipoxygenase metabolism after stimulation also influence the thrombogenic properties of ECs. First, we found that unstimulated ECs metabolize linoleic acid into 13-hydroxyoctadecadienoic acid (1 3-HODE) via the lipoxygenase pathway, the intracellular levels of which correlate inversely with EC thrombogenecity.6 Second, we and others have reported that, when ECs are stimulated by thrombin or by any of a number of cytokines, 13-HODE synthesis is inhibited and EC reactivity to platelets and cancer cells increases, both in vitro and in Finally, recent studies indicate that the increased EC reactivity is associated with an enhanced expression of the vitronectin receptor (VnR) on ihe apical surface of the ECs.I6,l7 Therefore, we hypothesized that these two phenomena are related and constitute an important mechanism by which EC reactivity for platelets, cancer cells, and other circulating blood cells is regulated.
T lar wall is not reactive to the circulating blood However, ECs acquire thrombogenic properties when they are stimulated by cytokines or thrombin, as shown both in vivo and in vitro. Thus, there is expression of plasminogen activator inhibit~r,~ expression of tissue f a~t o r ,~ and downregulation of thrombomod~lin,~ all of which can facilitate thrombogenesis. We have made a number of observations that suggest that changes in EC lipoxygenase metabolism after stimulation also influence the thrombogenic properties of ECs. First, we found that unstimulated ECs metabolize linoleic acid into 13-hydroxyoctadecadienoic acid (1 3-HODE) via the lipoxygenase pathway, the intracellular levels of which correlate inversely with EC thrombogenecity. 6 Second, we and others have reported that, when ECs are stimulated by thrombin or by any of a number of cytokines, 13-HODE synthesis is inhibited and EC reactivity to platelets and cancer cells increases, both in vitro and in Finally, recent studies indicate that the increased EC reactivity is associated with an enhanced expression of the vitronectin receptor (VnR) on ihe apical surface of the ECs.I6,l7 Therefore, we hypothesized that these two phenomena are related and constitute an important mechanism by which EC reactivity for platelets, cancer cells, and other circulating blood cells is regulated.
One possible mechanism by which 13-HODE may influence VnR expression is that 13-HODE may interact with the VnR, altering its conformational presentation and, therefore, its ability to recognize its specific ligands. Consistent with that possibility, Conforti et all8 found that the ability of the VnR to recognize von Willebrand factor (vWF), fibronectin, and vitronectin was dependent, in part, on the plasma membrane fatty acid(s) with which it associated. Other investigators have also reported that various fatty acids derived from activated platelets and polymorphonuclear leukocytes enhance the abilities of other argineglycine-aspartic acid (RGD)-recognizing integrins to bind their ligands in purified s y~t e m s . '~,~~ Thus, a number of investigators have provided evidence that lipid moieties may be important in modulating the ligand-binding properties of integrins. The studies cited above raise the possibility that HODE and the VnR were colocalized within unstimulated ECs. When ECs were stimulated, 13-HODE was no longer detectable, either in or outside the ECs, and the VnR was detected on the apical surface of the ECs. These changes were paralleled by increased vitronectin binding and increased platelet adhesion to the ECs. We suggest that colocalization of 13-HODE with VnR reflects a 13-HODE/ VnR interaction, confining the VnR in a nonadhesive form inside unstimulated ECs, and, as a result, the ECs are nonadhesive. When the ECs are stimulated, 13-HODE and VnR dissociate, allowing theVnR to relocate on the EC surface, where the VnR undergoes a conformational change resulting in increased EC adhesivity. 13-HODE may also be involved in these processes; namely, 13-HODE may downregulate the ability of VnR to recognize its ligands. If so, we postulated that 13-HODE and VnR should colocalize in ECs at a time when the ECs are not adhesive, and 13-HODE and VnR should dissociate at a time when the ECs are adhesive.
To test these possibilities, we determined the morphologic relationships between 13-HODE and VnR in unstimulated and interleukin-I (IL-1)-stimulated cultured human ECs, ligand binding, and platelet/EC adhesion, using intact cell preparations. Our results indicate that 13-HODE and VnR colocalize within unstimulated ECs, but dissociate when the ECs are stimulated, and then VnR is detected on the apical surface of the activated ECs. The latter is associated with a specific increase in vitronectin binding and an increase in platelet adhesion to that surface.
MATERIALS AND METHODS

Materials.
A rabbit Ig to human vWF was obtained from Dakopatts (Copenhagen, Denmark). Murine monoclonal antisera to the VnR a chain and the RGD recognizing site of the / 3 chain (LM 142 and LM609, respectively) were obtained from Dr D.A. Cheresh (Scripps Clinics, La Jolla, CA). The characteristics of these antisera are described in detail elsewhere.'' Antimouse Igconjugated to fluorescein was obtained from Dimension Laboratories Inc (Mississauga, Ontario, Canada). Human fibronectin and vitronectin were obtained from Dr F.A. Ofosu (Canadian Red Cross, Hamilton, Ontario, Canada). Human serum albumin was obtained from Sigma Chemicals (St Louis, MO). Human recombinant IL-la (IL-1) was obtained from Hoffman-La Roche (Nutley, NJ). The GRGDS and GRGES peptides were obtained from Peninsula Lab Inc (San Francisco, CA). Human umbilical cords were collected by the nursing staff of the Labour and Delivery unit of the McMaster Health Science Centre (Hamilton, Ontario, Canada). All tissue culture plasticware were obtained from Johns Laboratories (Toronto, Ontario, Canada). All cell culture media and supplements were obtained from GIBCO (Grand Island, NY). Linoleic acid and soybean lipoxygenase were obtained from Sigma Chemicals. 12510dine (100 pCi/mL, 13 mCi/pg) was obtained from New England Nuclear (Boston, MA).
Preparation IPHODE antiserrrim. 13-HODE was synthesized from linoleic acid using soybean lipoxygenase and purified by high performance liquid chromatography (HPLC) as previously described. 22 The purified 13-HODE was coupled to bovine serum albumin, using water soluble I-ethyl-3-(3dimethylaminopropyl)-carbodimide (EDC). The I3-HODE/albumin conjugate was purified by exhaustive dialysis against distilled water.
Six male rabbits were injected intramuscularly with the 13-HODE/albumin conjugate (250 pg of I3-HODE, suspended in Freund's complete adjuvant). Booster injections were administered to each rabbit at 6-week intervals for another 5 months. The rabbits then were anesthetized and exsanguinated via a carotid cannula. The blood was centrifuged at 3.000~ for 30 minutes to obtain cellfree serum, which was then passed over a DEAE-CL-6B column at a flow rate of 32 mL/h at a pressure difference of 42 cm. Fractions were collected at I-minute intervals for 30 minutes. Those fractions collected between 10 and 15 minutes were pooled, as they were identified as those fractions that contained the bulk of the IgG. These fractions were used throughout the study.
To determine the specificity and titre of the pooled antisera fractions (PS-I 3H), the following characterization was performed.
Known amounts ofauthentic 13-HODE, 15-hydroxyeicosatetraenoic acid ( 15-HETE), and 12-HETE (5 to 25 pg of each) were added to aliquots of normal pooled human cell-free plasma. Increasing amounts of PS-13H were then added to each aliquot. All aliquots were subsequently extracted and analyzed by HPLC as previously described." In addition. increasing amounts of authentic I3-HODE (0 to 300 pg) or 15-or 12-HETE (0 to 600 pg) were added to some ofthe EC monolayer preparations used in the immunofluorescence assays (described below) to determine which monohydroxide, ifany, blocked the detection of 13-HODE by the PS-13H in the immunofluorescence assay.
ECs isolated from human umbilical veins were grown to confluent monolayers according to the method of Jaffe et with the following modifications. The ECs were grown to confluence in T-25 flasks containing MI99 medium supple-
Human ECs crrrltiire.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From U/mL of penicillin, and 100 pglmL of EC growth supplement in an atmosphere of 95% air 5% C02. The confluent EC monolayers were harvested from the culture flasks, split 1:3, and grown to confluence on I% gelatincoated glass discs placed in Costar 24 wells. The cells grown were confirmed as ECs because they grew in the typical cobblestone formation and stained positive for v W F ?~ Preparation of nonpermeabilized and permeabilized EC monokayers. The EC monolayers on the discs were first rinsed twice with Hanks' Balanced Salt Solution (HBSS) and then incubated with 10 ng/mL of I L I in 500 pL fresh medium. Four hours later, the monolayers were fixed with either ( I ) I% paraformaldehyde in 0. I5 mol/L phosphate-buffered saline (PBS), pH 7.3, at 4°C for I8 hours: or (2) fixed with 1% paraformaldehyde in 0. I5 mol/L PBS as described above, and then permeabilized by incubating the cells with 2% Triton X-100 (vol/vol) for 3 minutes at 22°C. All ECs monolayers were then rinsed four times (5 min/wash) with 0.15 mol/L PBS and washed with 0.1% glycine (vol/vol) in Milloning's buffer ( I .68% NaH,PO, H20. 0.385% NaOH. 0.54% glucose, wt/ vol, pH 7.2) for 30 minutes. This method is described in detail elsewhere?' Localization Qf 13-HODE, IhR (Y chain, and VnR 0 chain. The fixed EC monolayer preparations were initially incubated with 10% normal goat serum for 30 minutes to saturate any nonspecific IgG binding sites, thereby blocking any nonspecific binding of the test antiserum. (Goat IgG was used because it does not crossreact with mouse or rabbit IgG.) The EC monolayers were then rinsed four times with 0. I5 mol/L PBS to wash off any unbound goat serum. Next, the EC monolayers were incubated with the test antibody diluted 1/100 at 22"C, ie, the rabbit polyclonal 13-HODE antiserum, PS-13H. or one ofthe murine monoclonal anti-VnR ascites. LM609 or LM 142. A dilution of 1: 100 was used for each antiserum, based on previous studies" or following the manufacturer's instructions. Ninety minutes later, the EC monolayers were rinsed four times with 0.15 mol/L PBS and incubated with 400 pL (16 pg) of the second antibody conjugated with either fluorescein or rhodamine red for I hour in the dark. The EC monolayers were again rinsed (in the dark) three times with 0.15 mol/L PBS and once with distilled water. Finally, the EC monolayers on the discs were placed in glycerine: 0.15 mol/L PBS (70:30, vol/vol), covered with tinfoil, and stored at 4°C for 18 hours. EC monolayer fluorescence was examined and photographed, using a Nikon Labophot microscope with an epifluorescence attachment or a Beckman confocal laser microscope (Mississavga, Ontario, Canada).
EC ligand-binding studies. EC monolayers on the discs were rinsed with HBSS and then incubated, one-half with 10 pg/mL of IL-1 in 500 pL fresh medium and the second half with 500 pL fresh medium. Four hours later, the monolayers were washed free of the medium and a second 500 pL of fresh medium containing increasing amounts of '251-vitronectin, -fibronectin, -fibrinogin, or -albumin was added. Other cell monolayers were incubated with known amounts of each 1Z51-labeled ligand and increasing concentrations of one ofthe four unlabeled ligands. Thirty minutes later, the monolayers were washed in HBSS and the amount of remaining radioactivity associated with each monolayer was determined as a measure of 'Z51-ligand displacement. Other EC monolayers were incubated with 5 mmol/L EGTA to detach the ECs from their underlying basement membranes. The EC-free membranes were washed three times with fresh medium and then incubated with increasing concentrations of the four ligands to determine the binding specificity of each ligand.
Blood from healthy volunteers who had not ingested aspirin during the previous 14 days was collected into acid citrate dextrose (0.35% ACD). Platelet-rich plasma was prepared by differential centrifugation (1 80g for 12 minutes). A platelet pellet was prepared by further centrifugation (1,700g for 12 minutes). The platelets were washed and radiolabeled with 3H-adenine as previously described." The 'H-platelets were washed and suspended at a concentration of 2 X 10' platelets/mL in 0.35% Tyrode's albumin solution (pH 7.35, 2 mmol/L CaCI,, 1 mmol/L 'H-labeled platelet preparation. MgC1,0.5 mg/mL fibrinogen, and 26 pmol/L unlabeled adenine), as previously described."
Platelet/EC adhesion assay. Confluent EC monolayers grown on the fibronectin-coated glass discs were rinsed with PBS containing 2 mmol/L Ca2+ and I mmol/L Mg2+ (pH 7.35) and incubated with IL-1, as described above. Four hours later, the medium was removed. A I-mL aliquot of 3H-platelet suspension was added to each monolayer and incubated for 30 minutes with gentle shaking in a 37°C waterbath. The EC monolayer-covered discs were then removed and gently washed three times in HBSS to remove any nonadherent platelets. The washed monolayers were placed into liquid scintillation vials and their radioactivities were measured to assess the number of platelets adherent/EC monolayer. This adhesion assay is described in detail elsewhere."
RESULTS
When unstimulated ECs, fixed with paraformaldehyde but not permeabilized, were incubated with PS-13H in PBS, and then viewed through a green filter, no 13-HODE could be detected on the surface of the ECs (data not shown because all photographs were blank, ie, there was no fluorescein fluorescence). However, when fixed and permeabilized ECs were incubated with the PS-l3H, there was a distinct punctate pattern of fluorescein fluorescence that appeared to be highlighted in specific vesicles (Fig IA) . These vesiclelike structures were situated immediately below the plasma membrane in the ECs, as determined by depth focusing ( Fig  1A) and confirmed by confocal laser microscopy (Fig 2) . When 300 pg of authentic 13-HODE (the average amount of 13-HODE produced by each EC monolayer) was added to the permeabilized ECs immediately before adding the PS-I 3H, all fluorescein fluorescence was blocked (Fig IC) . In contrast, when 150 to 600 pg of 12-or 15-HETE (lipoxygenase metabolites of arachidonic acid) was added, EC fluorescein fluorescence was unchanged (data not shown). These observations suggested that the PS-13H was specific for 13-HODE and that 13-HODE was localized to specific vesicles within the ECs.
The specificity of PS-13H for 13-HODE was confirmed by HPLC. When known amounts of 13-HODE, 12-HETE, and 15-HETE were added to pooled human plasma and then extracted and assayed by HPLC, an HPLC tracing such as that illustrated in Fig 3, inset A, was obtained. (The area under each peak is expressed as 100% recovery of each specific monohydroxide in the larger graph of Fig 3. ) When increasing amounts of PS-13H were added to the pooled plasmas containing the monohydroxides before extraction, there was a concentration-dependent decrease in the amount of 13-HODE recovered (Fig 3) . This is also illustrated as the decrease in area beneath the curve of peak 1 (see insets B, C, and D, Fig 3) . There was no decrease in 12-or 15-HETE recovery, ie, no change in area under the curve (Fig 3) . Furthermore, when comparable volumes ofan antiserum to vWF or to prostaglandin F,, 6-keto (PGF,,) were added, recoveries of all monohydroxides were unaffected (data not shown).
When the same unstimulated EC monolayers were incubated with LM 142 (which recognizes the VnR a chain) and viewed through a red filter, the pattern of rhodamine red fluorescence was identical to the pattern of fluorescein green For personal use only. on November 16, 2017. by guest www.bloodjournal.org From fluorescence obtained with the PS-13H antiserum (compare Fig I A and B) . These observations suggest that VnR is colocalized with 13-HODE within the same vesicle-like structures. When LM609 (which recognizes the RGD epitope of the VnR @ chain) was used, there was no EC rhodamine red fluorescence, either on the surface (Fig 4a) or inside the unstimulated ECs (Fig 4b) . These data indicate that the antibody-binding site of VnR @ was not accessible to the LM609, suggesting that the VnR present inside the unstimulated ECs was in a nonadhesive form.
When IL-I-stimulated ECs were fixed and permeabilized, there was no fluorescence of the EC monolayers, using either PS-13H (fluorescein , Fig 4c) or LM142 (rhodamine red [not shown], micrograph identical to Fig 4c) . However, when the stimulated ECs were only fixed and not permeabilized (to detect the surface antigens) and then incubated with LM609, there was a marked rhodamine fluorescence on the ECs, concentrated on the periphery of the EC surface (Fig   I   ID) . 13-HODE was not detectable on the surface of these cells (Fig 4d) . These data suggest that the VnR was now detectable in an adhesive form because the LM609 antigenic site is related to the RGD-adhesive site of the VnR @ subunit.
When increasing concentrations of 1251-labeled vitronectin, -fibronectin, -fibrinogen, or -albumin were added to unstimulated EC monolayers, each ligand bound to the ECs. This binding was rapidly saturated (Fig 5A, B, C, and D) , and did not differ among the four proteins. When these 1251-ligands were incubated with IL-I -stimulated ECs, IZ5l-vitronectin ligand binding increased significantly (P < .002), whereas the binding of the other three proteins remained unchanged at all concentrations tested. When increasing concentrations of unlabeled protein were added to unstimulated EC monolayers to which 5 pg/mL of '"I-vitronectin had been added (ie, to which 2.4 2 0. I pg bound/ monolayer), the unlabeled vitronectin displaced the I2'I-la- beled vitronectin in a concentration-related manner (Fig 6) . However, when the same concentrations of unlabeled vitronectin were added to IL-1-stimulated ECs (to which 3.9 +-0.1 pg/monolayer had bound), the unlabeled vitronectin did not displace the L251-labeled vitronectin (Fig 6) . Similar results were seen when 25 pg/mL of '251-labeled vitronectin was added to the unstimulated and IL-I-stimulated ECs (to which 6.4 f 0.1 and 8.3 f 0.1 pg/monolayer bound, respectively, see inset, Fig 6) . None of the other three proteins displaced the '251-labeled vitronectin from unstimulated or IL-I-stimulated ECs (data not shown). When the basement membranes underlying the EC cultures were incubated with the '251-labeled ligands, there was no difference in the amounts of vitronectin, fibronectin, fibrinogen, or albumin bound to the basement membrane surfaces (Fig 7) . These data indicate that the specific increase in vitronectin binding to IL-1 -stimulated EC monolayers was to the apical surface of the ECs and not to any basement membrane components exposed by EC retraction.
When 13-HODE and the VnR were colocalized inside the ECs (as detected by PS-13H and LM 142, respectively, and at a time when the RGD adhesive site of the p chain was not detectable by LM609), approximately 4 X lo3 platelets adhered/EC monolayer ( Table 1) . Adding either 100 pg of the GRGDS or GRGES peptide, or 100 pL of LM 142, LM609, or a fibronectin antibody, did not block this "basal" adhesion. However, when 13-HODE was no longer detectable and the adhesive domain of the VnR p chain was detectable (by LM609) on the apical surface of the ECs, ie, after IL-1 stimulation, platelet adhesion to the ECs increased (P < .01). This increase in platelet adhesion was only blocked by the GRGDS peptide and LM609, but not by the GRGES peptide or LM142 (Table 1) .
DISCUSSION
There is a large body of literature indicating that adhesion receptors are expressed on blood and vascular wall cells in response to injury or perturbation, thereby facilitating cell/ cell interactions. These receptors include the super family of adhesion receptors called integrins, which are reviewed elsewhere.2G3o However, the mechanism by which the expression of these adhesion receptors on the surface is regulated from within the cells is not well understood. Some studies suggest that the lipoxygenase metabolites of arachidonic and linoleic acids act as secondary messengers, modulating tumor cell/EC interactions via the protein kinase C p a t h~a y .~' Al- phosphorylation or other intracellular messenger proces~es.'~-*' Moreover, both endogenous and exogenous monohydroxides have been shown to modulate cell/cell interactions in a number of biologic systems both in vitro and ex vivo. These studies consistently show a significant relationship between the concentrations of the monohydroxides derived from linoleic and arachidonic acids (ie, 13-HODE and 5-, 12-, and 15-HETE) and blood cell/EC adhesion both in vitro and in vivo in the absence and presence of secondary messenger pathways; namely, 13-HODE is associated with decreased cell adhesivity, whereas 12-and 15-HETE are associated with increased cell adhesi~ity."'~,~~ There are similar inverse relationships between the adhesivity of intact and injured vessel walls and vessel wall 13-HODE synthesis, both in animal and human t i s s~e s . '~~'~,~~ Furthermore, a number of studies suggest that the adhesivity of the extracellular matrix underlying ECs varies inversely with the amount of 13-HODE associated with it.34 (It should be noted that another study has suggested that exogenously added 13-HODE has no effect on extracellular matrix a d h e~i v i t y .~~ However, in that study, the matrix was prepared by lysing the ECs with ammonium hydroxide, which may have inadvertently denatured the matrix proteins, thereby rendering them immune to conformational changes by the 13-HODE.) Thus, there is an abundance of data using both purified and biologic systems that suggest that lipids, in general, and monohydroxides, in particular, can directly alter the adhesivity of integrins. The results of our present study provide further evidence in this regard.
First, the present data support the possibility that the inverse relationship between 13-HODE and vessel wall adhesivity is a result of a direct interaction between 13-HODE One milliliter of 3H-adenine platelets (2 X 1 05/pL) was added to each EC monolayer (+lo ng/mL of IL-1 f 100 pg of GRGDS or GRGES, or + l o 0 pL of LM609 or LM142) and incubated for 30 minutes. Each EC monolayer was then washed and the number of 3H-platelets adherent was determined, based on EC monolayer radioactivity and 3H-platelet-specific activity. Other EC monolayers k IL-1 were fixed with paraformaldehyde rt Triton X-100
and incubated with one of the murine monoclonal antisera, LM 142 (a chain) and LM609 (p chain). Adding 100 pg of GRGES or 100 pL of LM 142 had no effect on platelet/EC adhesion + IL-1 . Data are expressed as mean f SEM, n = 9.
and VnR in ECs. Third, when VnR was detected on the surface of IL-I -stimulated ECs, it was only detected by LM609, which recognizes an epitope near or at the RGD adhesive site. This also suggests that VnR underwent some conformational change to allow LM609 access to that site. Moreover, its detection was paralleled by a specific increase in vitronectin binding, an increase in platelet adhesion, and no increase in fibronectin, fibrinogen, or albumin binding.
The observation that there were no differences in vitronectin, fibronectin, fibrinogen, and albumin binding to EC basement membrane preparations excludes the possibility that the difference in vitronectin binding before and after IL-1 stimulation is due to a specific binding of vitronectin to basement membrane components exposed after any EC retraction in response to the IL-I stimulation. (In addition, EC retraction was not detected by light or scanning microsThe explanation for why LM142 did not detect VnR on the surface of stimulated ECs is not entirely clear, but is also consistent with the VnR undergoing a structural alteration. For example, if LM 142 recognizes a tertiary epitope on the (Y chain of VnR, any conformational change in VnR after EC stimulation may alter the tertiary structure, thereby rendering VnR foreign to LM142. Alternatively, if the LM 142-recognizing epitope of VnR is located in or near the membrane spanning region of the a chain, that site may be masked by cytoskeletal or plasma membrane proteins after VnR relocalization. Neither possibility can be excluded.
The observation that 'Z51-labeled vitronectin was displaced from unstimulated ECs but not from IL-l-stimulated ECs by unlabeled vitronectin is consistent with recent studies that suggest that some VnR or VnR-like moiety is present on the apical surface of unstimulated ECS.'~,'~ However, the specific binding of vitronectin to the receptor under these conditions appears to be reversible because vitronectin was easily displaced. (Our immunofluorescent studies suggest, however, that the bulk of VnR in unstimulated ECs is intracellular, because EC permeabilization was required for VnR detection.) The observations that Iz5I-labeled vitronectin was no longer displaceable after EC IL-I stimulation is consistent with one of two possibilities: (1) either an entirely new receptor is expressed on the EC surface, or (2) the nonadhesive VnR undergoes conformation changes that rendered it more adhesive. The first possibility seems unlikely because the specific antibody (LM609) detected VnR on the EC surface under these stimulated condi-
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For personal use only. on November 16, 2017. by guest www.bloodjournal.org From 331 1 tions, and this was associated with a specific increase in vitronectin binding. The second possibility seems more likely because not only was there specific antibody and ligand binding, but there was also an irreversible binding of the ligand to the receptor, and this was associated with increase in platelet/EC adhesion. These results are consistent with (1) the observations of Orlando and C h e r e~h~~ that RGD-dependent ligand/integrin receptor binding leads to molecular stabilization between the two moieties, and (2) the observations that conformation modifications of integrins occur after cell s t i m~l a t i o n .~~*~ From the perspective of ECs, these changes appear to depend, in part, on a dissociation of VnR from 13-HODE and a relocalization of the VnR in an alternate lipid milieu, ie, the EC surface membrane phospholipid bilayer.
We conclude, therefore, that the lipid environment in which the VnR locates influences its conformational configuration and, hence, its adhesivity. The structural properties of VnR and 13-HODE are compatible with this possibility.
The membrane spanning region of both the a and p chains of VnR are lipophilic2',22; therefore, VnR will interact with 13-HODE or any other lipid. In addition, both VnR chains are rich in cysteine and are therefore capable of undergoing rapid conformational change^.^'^^^ We propose, therefore, that under basal conditions, ie, in unstimulated nonadhesive ECs, the lipophilic region of the VnR a and/or 0 chains interacts with 13-HODE in vesicles located immediately below the EC plasma membrane (Fig 8) . Under these conditions, the CY chain remains in a conformation such that its N-terminus masks the RGD-recognizing domain of the p chain, ie, masks the adhesive site of the 0 chain. This possibility is consistent with the observations of Smith and Cherish,36 who found that the CY chain of VnR blocks the RGD domain of the p chain in vitro. When ECs are stimulated and 13-HODE synthesis i s inhibited, VnR dissociates from any remaining 13-HODE and relocates in the EC phospholipid membrane bilayer. As a consequence, the a chain (which now is associated with another lipid moiety) undergoes a conformational change that unmasks the adhesive site of the p chain (Fig 8) . The latter possibility is consistent with the observations of Conforti et all8 and other^,'^.^^ and is consistent with our observations of a specific increase in ligand binding after EC stimulation. Such a model may also explain how 13-HODE, once released albuminally from ECs into the basement membrane underlying the ECs, renders other adhesive molecules less adhesive after vessel wall injury.12,13,32,34
